NMD Pharma
NMD Pharma - Inkef capital
NMD Pharma ApS Annual Report for 1 January - 31 December 2017
NMD bags €38M to run orphan neuromuscular disease trials | FierceBiotech
Contact — NMD Pharma
Management — NMD Pharma
NMD Pharma raises €38M (~USD 47 Million) SERIES A Financing to Advance Treatments of Neuromuscular Disorders
Investors — NMD Pharma
NMD Pharma
NMD Pharma company information, funding & investors | Dealroom.co
NMD Pharma Receives Approval to Start a combined Phase I/IIa Clinical Trial of NMD670 for the Treatment of Symptoms of Myasthenia Gravis
Management — NMD Pharma
NMD Pharma company information, funding & investors | Dealroom.co
NMD Pharma Initiates a Combined Phase I/IIa Clinical Trial of NMD670 for the Treatment of Symptoms of Myasthenia Gravis
Labiotech.eu on Twitter: "NMD Pharma, from @AarhusUni, is willing to tackle Neuromuscular Transmission Disorders #BioEquity2016… "
NMD Pharma to advance neuromuscular disorder therapies with €38m Series A round
NMD Pharma A/S | LinkedIn
Management — NMD Pharma
Management — NMD Pharma
NMD Pharma — NMD Pharma
NMD Pharma
Nmd Pharma A/S, Aarhus N | firma | krak.dk
NMD Pharma is Strengthening Muscles in Neuromuscular Disorders
Company Presentation
Big deal: NMD flexes series A muscles - Global University Venturing
